Opinion|Videos|July 18, 2024

Safety Data of Oral JAK Inhibitors in Atopic Dermatitis

An academic dermatologist discusses the safety profiles of abrocitinib and upadacitinib and provides clinical insights on patient monitoring practices.

Video content above is prompted by the following questions:

  • Are there differences in safety data from clinical trials vs. real-world studies? What has been your clinical experience with abrocitinib and upadacitinib?
  • Discuss your monitoring schedule for patients taking JAK inhibitors.
    • How do you modify your monitoring protocol according to patient characteristics and preferences?

Latest CME